R&G Pharma(301333.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
R&G Pharma
301333.SZ
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It offers drug clinical research and development integrated services. The company’s services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology services.
584.42 B
301333.SZMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
B
Life Sciences Tools and ServicesIndustry
Industry Ranking9/25
Industry medianC
Industry averageB
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE6.93%C
    • Profit Margin14.91%A
    • Gross Margin30.19%C
  • Growth ScoreB
    • Revenue YoY21.20%B
    • Net Profit YoY-6.70%C
    • Total Assets YoY5.12%C
    • Net Assets YoY7.32%B
  • Cash ScoreB
    • Cash Flow Margin80.30%C
    • OCF YoY21.20%B
  • Operating ScoreC
    • Turnover0.38C
  • Debt ScoreA
    • Gearing Ratio16.55%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Novo Nordisk announced the main clinical trial results of Reimagine 2. Novo Cagrisema demonstrated a weight loss effect of up to 14.2%. Cagrisema shows better weight loss effects compared to Semaglutide

    Wallstreetcn·
    SH
    688710
    +2.27%
    SZ
    159859
    -0.55%
    SH
    688105
    +0.38%
    Wallstreetcn·
    SH
    688710
    +2.27%
    SZ
    159859
    -0.55%
    SH
    688105
    +0.38%

    AI healthcare and AI pharmaceutical concepts are experiencing volatile adjustments, with PR falling over 18%, R&G Pharma down nearly 15%, and IMIC, BOJI CRO, GOODWILL, and Berry Genomics all dropping more than 5%

    Wallstreetcn·
    SZ
    301230
    -1.81%
    SZ
    301333
    -2.05%
    SZ
    000516
    -2.40%
    Wallstreetcn·
    SZ
    301230
    -1.81%
    SZ
    301333
    -2.05%
    SZ
    000516
    -2.40%

    R&G Pharma: Abnormal fluctuations in stock trading

    Zhitong·
    SZ
    301333
    -2.05%
    Zhitong·
    SZ
    301333
    -2.05%

    R&G Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 95.5668 million yuan, an increase of 13.21%

    Zhitong·
    SZ
    301333
    -2.05%
    Zhitong·
    SZ
    301333
    -2.05%

    R&G Pharma plans to launch an employee stock ownership plan in 2025 with a total funding not exceeding 15 million yuan

    Zhitong·
    SZ
    301333
    -2.05%
    Zhitong·
    SZ
    301333
    -2.05%
    © 2026 Longbridge｜Disclaimer